Your browser doesn't support javascript.
loading
Validation of the PHQ-9 in a psychiatric sample.
Beard, C; Hsu, K J; Rifkin, L S; Busch, A B; Björgvinsson, T.
Afiliación
  • Beard C; McLean Hospital/Harvard Medical School, United States. Electronic address: cbeard@mclean.harvard.edu.
  • Hsu KJ; McLean Hospital/Harvard Medical School, United States.
  • Rifkin LS; McLean Hospital/Harvard Medical School, United States.
  • Busch AB; McLean Hospital/Harvard Medical School, United States.
  • Björgvinsson T; McLean Hospital/Harvard Medical School, United States.
J Affect Disord ; 193: 267-73, 2016 Mar 15.
Article en En | MEDLINE | ID: mdl-26774513
BACKGROUND: The PHQ-9 was originally developed as a screener for depression in primary care and is commonly used in medical settings. However, surprisingly little is known about its psychometric properties and utility as a severity measure in psychiatric populations. We examined the full range of psychometric properties of the PHQ-9 in patients with a range of psychiatric disorders (i.e., mood, anxiety, personality, psychotic). METHODS: Patients (n=1023) completed the PHQ-9 upon admission and discharge from a partial hospital, as well as other self-report measures of depression, anxiety, well-being, and a structured diagnostic interview. RESULTS: Internal consistency was good (α=.87). The PHQ-9 demonstrated a strong correlation with a well-established measure of depression, moderate correlations with related constructs, a weak correlation with a theoretically unrelated construct (i.e., disgust sensitivity), and good sensitivity to change, with a large pre- to post-treatment effect size. Using a cut-off of ≥13, the PHQ-9 demonstrated good sensitivity (.83) and specificity (.72). A split-half exploratory factor analysis/confirmatory factor analysis suggested a two-factor solution with one factor capturing cognitive and affective symptoms and a second factor reflecting somatic symptoms. Psychometric properties did not differ between male and female participants. LIMITATIONS: No clinician-rated measure of improvement, and the sample lacked ethnoracial diversity. CONCLUSIONS: This first comprehensive validation of the PHQ-9 in a large, psychiatric sample supported its use as a severity measure and as a measure of treatment outcome. It also performed well as a screener for a current depressive episode using a higher cut-off than previously recommended for primary care samples.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Tamizaje Masivo / Encuestas y Cuestionarios / Trastornos Mentales Tipo de estudio: Diagnostic_studies / Prognostic_studies / Qualitative_research / Screening_studies Idioma: En Revista: J Affect Disord Año: 2016 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Tamizaje Masivo / Encuestas y Cuestionarios / Trastornos Mentales Tipo de estudio: Diagnostic_studies / Prognostic_studies / Qualitative_research / Screening_studies Idioma: En Revista: J Affect Disord Año: 2016 Tipo del documento: Article